KRIBIOLISA™ Cetuximab (ERBITUX) ELISA
₹34,000.00
Enzyme Immunoassay for the estimation of Cetuximab (ERBITUX) in serum and plasma.
Key features:
1. Developed using highly specific monoclonal anti-idiotypic antibodies in a sandwich assay format
2. Validated as per international bioassay validation guidelines
3. Recovery: 80-120%
4. Precision CV <10%
Availability: 3 – 4 Weeks | Pack Size: 1 x 96 wells
Powered by BiozDescription
Background:
Cetuximab is an epidermal growth factor receptor (EGFR) inhibitor used for the treatment of metastatic colorectal cancer, metastatic non-small cell lung cancer and head and neck cancer. Cetuximab is a chimeric (mouse/human) monoclonal antibody given by intravenous infusion that is distributed under the trade name Erbitux in the U.S. and Canada by the drug company Bristol-Myers Squibb and outside the U.S. and Canada by the drug company Merck KGaA. In Japan, Merck KGaA, Bristol-Myers Squibb and Eli Lilly have a co-distribution. In July 2009, FDA approved Cetuximab (Erbitux) for treatment of colon cancer with wild-type KRAS, since it had little or no effect in colorectal tumors harboring a KRAS mutation (this also applied to the EGFR antibody panitumumab).
Intended Use:
For Estimation of Cetuximab (ERBITUX) in human serum and plasma. Please note the kit has not been optimized to be used for any other animal species. Should you require a specific sera tested, please connect with us at sales@krishgen.com for optimization.
Principle:
The method employs the quantitative sandwich enzyme immunoassay technique. Antibodies to Cetuximab are pre-coated onto microwells. Samples and standards are pipetted into microwells and human Cetuximab present in the sample are bound by the capture antibody. Then a HRP (horseradish peroxidase) conjugated anti-Cetuximab antibody is pipetted and incubated. After washing microwells in order to remove any non-specific binding, the ready to use substrate solution (TMB) is added to microwells and color develops proportionally to the amount of Cetuximab in the sample. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.
If you have published a paper by using any of our ELISA since 01/01/2023, kindly fill out the “Krishgen Publication Reward Application Form” with complete information and send it by at email: info@krishgen.com, with the subject “Krishgen Publication Reward”. We will get back to you with the Amazon / Krishgen Credit Reward after we confirm it ASAP!
Additional information
| Calibration Range | 10 ng/ml – 640 ng/ml |
|---|---|
| Sensitivity | 80ng/ml |
| Detection Method | Colorimetric |
| Specificity | 80% – 120% to Cetuximab (ERBITUX) |
| Cross Reactivity | < 0.5% cross-reactivity observed with related biomarker. |
| Interference | No significant interference observed with available related molecules. |
| Storage Temprature | Store the unopened product at 2-8 Degree Celcius. Concentrated detection conjugate should be stored at -20 Degree Celcius. Do not use past expiration date. |
| Shipping Temperature | 2-8 Degree Celcius. Concentrated detection conjugate ship at -20 Degree Celcius in a second box. Freight applicable for both. |
| Regulatory Status | Research Use Only |
| Research Area | Cancer |
| Entez Gene ID | ABP-494 Human |
| Alternate Names / Synonyms | Cetuximab, C?tuximab, Cetuximabum |
| Alternate Drug Brand Names | Erbitux |
| Drug Bank Accession Number | DB00002 |
| ELISA Type | Direct Sandwich Assay |